Characterization of Non-Specific Uptake and Retention Mechanisms of [(177)Lu]Lu-PSMA-617 in the Salivary Glands

The radionuclide therapy [(177)Lu]Lu-PSMA-617 was recently FDA-approved for treatment of metastatic castration-resistant prostate cancer. Salivary gland toxicity is currently considered as the main dose-limiting side effect. However, its uptake and retention mechanisms in the salivary glands remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Heynickx, Nathalie, Segers, Charlotte, Coolkens, Amelie, Baatout, Sarah, Vermeulen, Koen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224201/
https://www.ncbi.nlm.nih.gov/pubmed/37242475
http://dx.doi.org/10.3390/ph16050692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224201/
https://www.ncbi.nlm.nih.gov/pubmed/37242475
http://dx.doi.org/10.3390/ph16050692

Ejemplares similares